Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Oncogene ; 36(17): 2394-2404, 2017 04 27.
Article in English | MEDLINE | ID: mdl-27941874

ABSTRACT

Colorectal cancer (CRC) is a complex disease with still unsatisfactory prognosis even in western societies, although substantial progress has been made in pre-screening programs, surgical techniques and targeted therapy options. Mediator of motility-1 (Memo-1) was previously recognized as an important effector of cell migration downstream of receptor tyrosine kinase signaling in breast cancer. This study identified Memo-1 as frequently overexpressed in CRC and established a close link between extracellular HER2 activation, AhR/ARNT transcriptional activity and Memo-1 expression. Dissection of the hMemo-1 gene promoter using reporter assays and chromatin IP techniques revealed recruitment of Aryl hydrocarbon receptor (AhR)/Aryl hydrocarbon receptor nuclear-translocator (ARNT) complex, which positively influenced Memo-1 expression in cancer cells. We found that Memo-1 depletion negatively influenced the cellular actin network and that its expression is required for HER2-mediated cell migration and invasion. Moreover, analyses of Memo-1 expression in primary CRC revealed correlation with clinical parameters that point to Memo-1 as a new prognostic factor of aggressive disease in CRC patients. Altogether, these observations demonstrate that Memo-1 is an important downstream regulator of HER2-driven CRC cell migration and invasion through connecting extracellular signals from membrane to the cytoskeletal actin network.


Subject(s)
Colorectal Neoplasms/pathology , Gene Expression Regulation, Neoplastic , Nonheme Iron Proteins/genetics , Proteins/metabolism , Receptor, ErbB-2/metabolism , Receptor, ErbB-3/metabolism , Receptors, Aryl Hydrocarbon/metabolism , Cell Line, Tumor , Cell Movement , Disease Progression , Humans , Intracellular Signaling Peptides and Proteins , Neoplasm Invasiveness , Promoter Regions, Genetic/genetics , Signal Transduction
2.
Br J Pharmacol ; 171(4): 849-58, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24024905

ABSTRACT

UNLABELLED: In recent years, it has become clear that the current standard therapeutic options for pancreatic cancer are not adequate and still do not meet the criteria to cure patients suffering from this lethal disease. Although research over the past decade has shown very interesting and promising new therapeutic options for these patients, only minor clinical success was achieved. Therefore, there is still an urgent need for new approaches that deal with early detection and new therapeutic options in pancreatic cancer. To provide optimal care for patients with pancreatic cancer, we need to understand better its complex molecular biology and thus to identify new target molecules that promote the proliferation and resistance to chemotherapy of pancreatic cancer cells. In spite of significant progress in curing cancers with chemotherapy, pancreatic cancer remains one of the most resistant solid tumour cancers and many studies suggest that drug-resistant cancer cells are the most aggressive with the highest relapse and metastatic rates. In this context, activated Notch signalling is strongly linked with chemoresistance and therefore reflects a rational new target to circumvent resistance to chemotherapy in pancreatic cancer. Here, we have focused our discussion on the latest research, current therapy options and recently identified target molecules such as Notch-2 and the heparin-binding growth factor midkine, which exhibit a wide range of cancer-relevant functions and therefore provide attractive new therapeutic target molecules, in terms of pancreatic cancer and other cancers also. LINKED ARTICLES: This article is part of a themed section on Midkine. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.issue-4.


Subject(s)
Cytokines/metabolism , Pancreatic Neoplasms/metabolism , Animals , Humans , Midkine , Pancreatic Neoplasms/genetics , Receptors, Notch/metabolism , Signal Transduction
3.
Chirurg ; 83(8): 719, 722-5, 2012 Aug.
Article in German | MEDLINE | ID: mdl-22878577

ABSTRACT

Bleeding and perforation in esophageal cancer patients are rare but associated with a high morbidity and mortality. Because of disappointing results after primary surgical exploration and resection endoscopic intervention was introduced as the primary treatment option with an improved outcome. Aortoesophageal and esophagobronchial fistulas may occur spontaneously or secondary to stenting of the esophagus. They are uncommon but fatal if untreated. The first option is prompt placement of a stent graft as a bridging solution followed by surgical treatment.


Subject(s)
Adenocarcinoma/surgery , Emergencies , Esophageal Fistula/surgery , Esophageal Neoplasms/surgery , Esophageal Perforation/surgery , Gastrointestinal Hemorrhage/surgery , Adenocarcinoma/diagnosis , Adenocarcinoma/mortality , Aortic Diseases/diagnosis , Aortic Diseases/mortality , Aortic Diseases/surgery , Blood Vessel Prosthesis Implantation/mortality , Bronchial Fistula/diagnosis , Bronchial Fistula/mortality , Bronchial Fistula/surgery , Esophageal Fistula/diagnosis , Esophageal Fistula/mortality , Esophageal Neoplasms/diagnosis , Esophageal Neoplasms/mortality , Esophageal Perforation/diagnosis , Esophageal Perforation/mortality , Esophagoscopy/methods , Esophagoscopy/mortality , Gastrointestinal Hemorrhage/diagnosis , Gastrointestinal Hemorrhage/mortality , Humans , Prognosis , Reoperation/methods , Reoperation/mortality , Stents , Survival Rate , Vascular Fistula/diagnosis , Vascular Fistula/mortality , Vascular Fistula/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...